Traws Pharma Inc (TRAW)

$1.43 -0.18 (-11.18%)
Market Cap 12.87M
Revenue (ttm) 230,000.00
Net Income (ttm) -166.52M
EPS (ttm) N/A
PE Ratio 0.02
Forward PE N/A
Profit Margin -72,400.00%
Debt to Equity Ratio 0.00
Volume 240,300
Avg Vol 336,204
Day's Range N/A - N/A
Shares Out 7.99M
Stochastic %K 8%
Beta 1.78
Analysts Strong Sell
Price Target $7.25

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3680
Fax: 267 759 3681
Address:
12 Penns Trail, Newtown, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 3:11 AM
$TRAW RSI: 30.77, MACD: -0.0518 Vol: 0.33, MA20: 2.05, MA50: 1.82 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Schube1255
Schube1255 Feb. 21 at 1:07 AM
$TRAW 🎱
0 · Reply
willopond210
willopond210 Feb. 20 at 11:45 PM
$TRAW should just be an admin correction to address the mutigenity concern. Bought some more today. By time they remove the hold this will have already taken off. NFA.
0 · Reply
kyly2
kyly2 Feb. 20 at 5:50 PM
$TRAW Subirá
0 · Reply
jstocks100
jstocks100 Feb. 20 at 12:36 PM
$TRAW
0 · Reply
Dwarn2021
Dwarn2021 Feb. 19 at 4:28 PM
$TRAW flushing retail out - some big buys today. I’ll file a 13g likely within the next 10 days. Don‘t be shortsighted. Base case remains. Probably a data or language clarification.
0 · Reply
jstocks100
jstocks100 Feb. 19 at 4:15 PM
$TRAW
0 · Reply
Jbjb90
Jbjb90 Feb. 19 at 3:26 PM
$TRAW down big but down big on low volume, sky isnt falling yet
0 · Reply
UberFloyd
UberFloyd Feb. 19 at 3:10 PM
$TRAW can't catch a break. Positive PR never seems to matter as much as negative. For sure will be adding to my position if it hits those Dec lows tho
0 · Reply
notreload_ai
notreload_ai Feb. 19 at 2:48 PM
$TRAW stock dropped after the FDA placed a clinical hold on its monthly flu prevention pill due to mutagenicity concerns. Positive COVID drug results couldn’t offset the news. https://notreload.xyz/traws-pharma-falls-after-fda-puts-flu-drug-application-on-clinical-hold/
0 · Reply
Latest News on TRAW
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Feb 19, 2026, 7:30 AM EST - 4 days ago

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Jan 13, 2026, 7:00 AM EST - 5 weeks ago

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Oct 30, 2025, 12:00 PM EDT - 4 months ago

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Oct 22, 2025, 6:40 PM EDT - 4 months ago

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Oct 14, 2025, 7:00 AM EDT - 4 months ago

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 18, 2025, 7:00 AM EDT - 6 months ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 1:14 PM EDT - 6 months ago

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 14, 2025, 7:00 AM EDT - 6 months ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Aug 8, 2025, 7:00 AM EDT - 7 months ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 30, 2025, 6:30 AM EDT - 8 months ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Jun 3, 2025, 7:00 AM EDT - 9 months ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025, 8:00 AM EDT - 9 months ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025, 7:00 AM EDT - 10 months ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Apr 1, 2025, 8:50 PM EDT - 11 months ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 11 months ago

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 26, 2025, 7:30 AM EDT - 11 months ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 25, 2025, 7:30 AM EDT - 11 months ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Mar 3, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 28, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 23, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Jan 10, 2025, 5:55 PM EST - 1 year ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 30, 2024, 8:00 AM EST - 1 year ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 1 year ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Dec 23, 2024, 7:00 AM EST - 1 year ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024, 4:30 PM EST - 1 year ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 20, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 20, 2024, 9:02 AM EDT - 1 year ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 2 years ago

Traws Pharma Announces New Employee Inducement Grants

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Mar 8, 2024, 8:00 AM EST - 2 years ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Dec 8, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 28, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 8:18 PM EST - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Nov 2, 2023, 10:37 AM EDT - 2 years ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Onconova Expands Leadership Team with Two Key Appointments

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 9:08 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 9:11 PM EDT - 3 years ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023, 4:18 PM EDT - 3 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 3:11 AM
$TRAW RSI: 30.77, MACD: -0.0518 Vol: 0.33, MA20: 2.05, MA50: 1.82 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Schube1255
Schube1255 Feb. 21 at 1:07 AM
$TRAW 🎱
0 · Reply
willopond210
willopond210 Feb. 20 at 11:45 PM
$TRAW should just be an admin correction to address the mutigenity concern. Bought some more today. By time they remove the hold this will have already taken off. NFA.
0 · Reply
kyly2
kyly2 Feb. 20 at 5:50 PM
$TRAW Subirá
0 · Reply
jstocks100
jstocks100 Feb. 20 at 12:36 PM
$TRAW
0 · Reply
Dwarn2021
Dwarn2021 Feb. 19 at 4:28 PM
$TRAW flushing retail out - some big buys today. I’ll file a 13g likely within the next 10 days. Don‘t be shortsighted. Base case remains. Probably a data or language clarification.
0 · Reply
jstocks100
jstocks100 Feb. 19 at 4:15 PM
$TRAW
0 · Reply
Jbjb90
Jbjb90 Feb. 19 at 3:26 PM
$TRAW down big but down big on low volume, sky isnt falling yet
0 · Reply
UberFloyd
UberFloyd Feb. 19 at 3:10 PM
$TRAW can't catch a break. Positive PR never seems to matter as much as negative. For sure will be adding to my position if it hits those Dec lows tho
0 · Reply
notreload_ai
notreload_ai Feb. 19 at 2:48 PM
$TRAW stock dropped after the FDA placed a clinical hold on its monthly flu prevention pill due to mutagenicity concerns. Positive COVID drug results couldn’t offset the news. https://notreload.xyz/traws-pharma-falls-after-fda-puts-flu-drug-application-on-clinical-hold/
0 · Reply
Dwarn2021
Dwarn2021 Feb. 19 at 2:45 PM
$TRAW moderna just had a reversal after an FDA hiccup. All is not lost. They will get guidance by mid March so it could be before. This is 2/3 positive news release and 1/3 be patient. Even an eventual 100M buyout is a 8x+. Someone was just diagnosed with bird flu in India and another in Cambodia all in the last week. cases in wildlife worldwide are rampant. Senate just passed 5.5B to deal with a new unidentified yet to occur influenza pandemic in early February. I’ll take your shares.
0 · Reply
penny_z
penny_z Feb. 19 at 1:40 PM
$TRAW CLINICAL Hold by FDA is a death sentence for their flu pipeline. 💀 Don't get fooled by the COVID news, that's just a distraction. Mutagenicity issues = Massive delays and expensive new trials. Cash burn will be insane now. Taking my loss and out. 📉🚩 #FDA #ClinicalHold
2 · Reply
OpenOutcrier
OpenOutcrier Feb. 19 at 1:26 PM
$TRAW (-26.4% pre) FDA informed the Company that its US IND for tivoxavir marboxil was being placed on clinical hold due to concerns with the mutagenicity data package. https://ooc.bz/l/93838
0 · Reply
Dwarn2021
Dwarn2021 Feb. 19 at 1:23 PM
$TRAW this should be resolved by March 16 after FDA provides guidance on TXM. excellent buying opportunity. i am picking up shares in pre market to lower average.
0 · Reply
ka1954
ka1954 Feb. 19 at 1:22 PM
$TRAW fucking never trust a biotech. 95% of them are turds
0 · Reply
GildedAge01
GildedAge01 Feb. 19 at 12:47 PM
$TRAW what’s going on ????
0 · Reply
Jbjb90
Jbjb90 Feb. 19 at 12:36 PM
$TRAW https://www.stocktitan.net/news/TRAW/traws-pharma-completes-analysis-of-ratutrelvir-clinical-study-in-zmy8vrjjxhu8.html
0 · Reply
ka1954
ka1954 Feb. 19 at 12:35 PM
$TRAW fucked up. was better to be traded than just waiting for 4+
0 · Reply
DaBullRunner
DaBullRunner Feb. 19 at 12:34 PM
$TRAW watching closely
0 · Reply
TheTradeXchange
TheTradeXchange Feb. 19 at 12:31 PM
$TRAW - Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
0 · Reply
TriggerScout
TriggerScout Feb. 18 at 9:27 AM
$TRAW Nano-cap where liquidity constraints exaggerate moves; filings are essential reading.
0 · Reply
Johnny_Drama
Johnny_Drama Feb. 17 at 5:48 PM
$TRAW
3 · Reply